Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company is founded by the former founders of Prosensa and Jerini and reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. Pharvaris uses small molecules to advance potent, orally available compounds targeting HAE. POC demonstrated in a monkey model and it’s applicable to all patients in HAE – the profile allows for clear differentiation in both on-demand and prophylactic settings. HAE is a significant and growing market with total 2018 sales around $2b. The company will be initiating a Phase I trial in 1H19.
Leiden Bio Science Park
J.H. Oortweg 21
Leiden, 2333 BD
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.